BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25093289)

  • 21. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal debulking surgery is an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma.
    Wang PH; Yuan CC; Shyong WY; Chiang SC; Chao JY; Yen MS; Ng HT
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Mar; 63(3):220-5. PubMed ID: 10746418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer.
    van de Laar R; IntHout J; Van Gorp T; Verdonschot S; van Altena AM; Gerestein CG; Massuger LF; Zusterzeel PL; Kruitwagen RF
    Br J Cancer; 2014 Jan; 110(1):42-8. PubMed ID: 24253502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
    Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
    Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nomogram for 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer.
    Nieuwenhuyzen-de Boer GM; Gerestein CG; Eijkemans MJ; Burger CW; Kooi GS
    Eur J Gynaecol Oncol; 2016; 37(1):63-8. PubMed ID: 27048112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.
    van Altena AM; Karim-Kos HE; de Vries E; Kruitwagen RF; Massuger LF; Kiemeney LA
    Gynecol Oncol; 2012 Jun; 125(3):649-54. PubMed ID: 22370602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.
    Iwase H; Takada T; Iitsuka C; Nomura H; Abe A; Taniguchi T; Takizawa K
    J Gynecol Oncol; 2015 Oct; 26(4):303-10. PubMed ID: 26197771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment and verification of the nomogram that predicts the 3-year recurrence risk of epithelial ovarian carcinoma.
    Hu J; Jiao X; Zhu L; Guo H; Wu Y
    BMC Cancer; 2020 Sep; 20(1):938. PubMed ID: 32993522
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
    Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
    J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy.
    Lee CK; Asher R; Friedlander M; Gebski V; Gonzalez-Martin A; Lortholary A; Lesoin A; Kurzeder C; Largillier R; Hilpert F; Hardy-Bessard AC; Kaminsky MC; Poveda A; Pujade-Lauraine E
    Eur J Cancer; 2019 Aug; 117():99-106. PubMed ID: 31279306
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
    Zhou M; Li L; Wang X; Wang C; Wang D
    Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
    Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
    Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A preoperative low cancer antigen 125 level (≤25.8 mg/dl) is a useful criterion to determine the optimal timing of interval debulking surgery following neoadjuvant chemotherapy in epithelial ovarian cancer.
    Morimoto A; Nagao S; Kogiku A; Yamamoto K; Miwa M; Wakahashi S; Ichida K; Sudo T; Yamaguchi S; Fujiwara K
    Jpn J Clin Oncol; 2016 Jun; 46(6):517-21. PubMed ID: 26977055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer.
    Kim SI; Song M; Hwangbo S; Lee S; Cho U; Kim JH; Lee M; Kim HS; Chung HH; Suh DS; Park T; Song YS
    Cancer Res Treat; 2019 Jul; 51(3):1144-1155. PubMed ID: 30453728
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
    Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
    J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
    Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
    Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.
    Zhang M; Zhuang G; Sun X; Shen Y; Zhao A; Di W
    J Ovarian Res; 2015 Oct; 8():67. PubMed ID: 26490766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.